BrainSignsLab - Cerebrospinal fluid in COVID-19 neurological

Journal article

María A García, Paula Barreras, A. Lewis, G. Pinilla, L. Sokoll, T. Kickler, H. Mostafa, Mario Caturegli, A. Moghekar, K. Fitzgerald, C. Pardo
medRxiv, 2021

Semantic Scholar DOI PubMed

Cite

APA Click to copy
García, M. A., Barreras, P., Lewis, A., Pinilla, G., Sokoll, L., Kickler, T., … Pardo, C. (2021). Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation. MedRxiv.

Chicago/Turabian Click to copy
García, María A, Paula Barreras, A. Lewis, G. Pinilla, L. Sokoll, T. Kickler, H. Mostafa, et al. “Cerebrospinal Fluid in COVID-19 Neurological Complications: No Cytokine Storm or Neuroinflammation.” medRxiv (2021).

MLA Click to copy
García, María A., et al. “Cerebrospinal Fluid in COVID-19 Neurological Complications: No Cytokine Storm or Neuroinflammation.” MedRxiv, 2021.

BibTeX Click to copy

@article{mar2021a,
  title = {Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation.},
  year = {2021},
  journal = {medRxiv},
  author = {García, María A and Barreras, Paula and Lewis, A. and Pinilla, G. and Sokoll, L. and Kickler, T. and Mostafa, H. and Caturegli, Mario and Moghekar, A. and Fitzgerald, K. and Pardo, C.}
}

Abstract

BACKGROUND. Neurological complications occur in COVID-19. We aimed to examine cerebrospinal fluid (CSF) of COVID-19 subjects with neurological complications and determine presence of neuroinflammatory changes implicated in pathogenesis. METHODS. Cross-sectional study of CSF neuroinflammatory profiles from 18 COVID-19 subjects with neurological complications categorized by diagnosis (stroke, encephalopathy, headache) and illness severity (critical, severe, moderate, mild). COVID-19 CSF was compared with CSF from healthy, infectious and neuroinflammatory disorders and stroke controls (n=82). Cytokines (IL-6, TNF-alpha, IFN-gamma, IL-10, IL-12p70, IL-17A), inflammation and coagulation markers (high-sensitivity-C Reactive Protein [hsCRP], ferritin, fibrinogen, D-dimer, Factor VIII) and neurofilament light chain (NF-L), were quantified. SARS-CoV2 RNA and SARS-CoV2 IgG and IgA antibodies in CSF were tested with RT-PCR and ELISA. RESULTS. CSF from COVID-19 subjects showed a paucity of neuroinflammatory changes, absence of pleocytosis or specific increases in pro-inflammatory markers or cytokines (IL-6, ferritin, or D-dimer). Anti-SARS-CoV2 antibodies in CSF of COVID-19 subjects (77%) were observed despite no evidence of SARS-CoV2 viral RNA. A similar increase of pro-inflammatory cytokines (IL-6, TNF-alpha;, IL-12p70) and IL-10 in CSF of COVID-19 and non-COVID-19 stroke subjects was observed compared to controls. CSF-NF-L was elevated in subjects with stroke and critical COVID-19. CSF-hsCRP was present almost exclusively in COVID-19 cases. CONCLUSION. The paucity of neuroinflammatory changes in CSF of COVID-19 subjects and lack of SARS-CoV2 RNA do not support the presumed neurovirulence of SARS-CoV2 or neuroinflammation in pathogenesis of neurological complications in COVID-19. Elevated CSF-NF-L indicates neuroaxonal injury in COVID-19 cases. The role of CSF SARS-CoV2 IgG antibodies is still undetermined.